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In the evaluation of pharmacologic therapies, the controlled
clinical trial is the preferred design. When clinical trial results
are not available, the alternative designs are observational
epidemiologic studies. A traditional concern about the valid-
ity of findings from epidemiologic studies is the possibility of
bias from uncontrolled confounding. In studies of pharmaco-
logic therapies, confounding by indication may arise when a
drug treatment serves äs a marker for a clinical characteristic
or medical condition that triggers the use of the treatment and
that, at the same time, increases the risk of the outcome under
study. Confounding by indication is not conceptually differ-
ent from confounding by other factors, and the approaches to
detect and control for confounding — matching, stratifica-
tion, restriction, and multivariate adjustment — are the same.
Even after adjustment for known risk factors, residual con-
founding may occur because of measurement error or unmea-
sured or unknown risk factors. Although residual confound-
ing is difficult to exclude in observational studies, there are
limits to what this "unknown" confounding can explain. The
degree of confounding depends on the prevalence of the
putative confounding factor, the level of its association with
the disease, and the level of its association with the exposure.
For example, a confounding factor with a prevalence of 20%
would have to increase the relative odds of both outcome and
exposure by factors of 4 to 5 before the relative risk of 1.57
would be reduced to 1.00. Observational studies have pro-
vided important scientific evidence about the risks associated
with several risk factors, including drug therapies, and they
are often the only Option for assessing safety. Understanding
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the methods to detect and control for confounding makes it
possible to assess the plausibility of claims that confounding
is an alternative explanation for the findings of particular
studies. J Am Geriatr Soc 47:749-754,1999.
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In the evaluation of pharmacologic therapies, the controlledclinical trial is the preferred design because randomization
generally produces groups whose probability of the outcome
of interest is comparable.1 With adequate sample sizes, ran-
domization balances both known and unknown risk factors
for the outcome. For many pharmacologic therapies, how-
ever, the results of randomized clinical trials are not avail-
able.2 For instance, many of the clinical trials comparing the
newer antihypertensive agents, including angiotensin-
converting enzyme inhibitors and calcium channel blockers,
with low-dose diuretic therapy in terms of outcomes such äs
myocardial infarction are just now in progress.3 In the ab-
sence of clinical trials results, the alternative designs are
observational epidemiologic studies.
A traditional concern about the validity of findings from
epidemiologic studies is the possibility of bias from uncon-
trolled confounding. Case-control and cohort studies com-
pare outcomes between groups with different exposures, and
confounding arises when the groups under comparison differ
in other ways than the exposure alone. These differenefes may
include demographic factors, behaviors, clinical characteris-
tics, medical conditions, or treatments. Some exposures are
more liable to confounding than others. When the outcome is
an unintended or unanticipated effect of the exposure — the
unexpected thrombotic complications such äs deep venous
thrombosis and pulmonary embolism associated with the
early oral contraceptives are a good example — confounding
is less likely to occur than when the outcome is an intended
effect of the exposure.4'5
The potential problem of intended effects is likely to arise
when the exposure of interest is a medication or a medical
procedure, and it is often called confounding by indication
or, sometimes, channeling bias.6"9 In the example of the
association between myocardial infarction and the use of
calcium channel blockers among hypertensive patients,10 the
argument runs äs follows: calcium channel blockers are used
to treat angina pectoris äs well äs hypertension; angina pec-
JAGS 47:749-754, 1999
© 1999 by the American Genatrics Society 0002-8614/99/S3.50
750 PSATYETAL. JUNE 1999-VOL. 47, NO. 6 JAGS
toris is a major risk factor for myocardial infarction; because
the use of calcium channel blockers is simply a marker for
high-risk angina patients, the association between the use of
calcium channel blockers and the incidence of myocardial
infarction is, therefore, not a causal one. This argument,
offered by a number of commentators,11"14 describes per-
fectly the problem of confounding by indication. The purpose
of this article is to describe several analytic approaches that
make it possible in some observational studies of medica-
tion effects to detect and control for confounding by indi-
cation.
Definition and Analytic Approaches
Consider an observational study to determine whether a
certain exposure affects the risk of a certain outcome. To be a
confounder in this study, the factor must be associated with
both the outcome and the exposure. Often, confounders are
contributing causes of the outcome although other noncausal
associations with the outcome Status may also qualify: for
example, if the factor affects recognition of the outcome.
Factors whose association with the exposure derives solely
from being a consequence of the exposure do not qualify äs
confounders; they may instead be mediating variables.
Confounding by indication may arise when a drug treat-
ment serves äs a marker for a clinical characteristic or medical
condition that triggers the use of the treatment and that, at
the same time, increases the risk of the outcome under study.
Confounding by indication is not conceptually different from
confounding by other factors, and the approaches to control
for confounding by indication are the same: matching, strat-
ification, restriction, and multivariate adjustment.15""18
In a stratified analysis, for instance, the study population
is divided into two groups according to the presence or
absence of the potential confounding factor, and the associ-
ation between the exposure and the outcome is examined
separately within each stratum. Depending on the results of
the stratified analysis, adjustment or restriction may be ap-
propriate. Table l presents several hypothetical examples
based on an unadjusted relative risk of 3. In example No. l,
the stratum-specific relative risks are both equal to the unad-
justed relative risk of 3. Here, there is no confounding, and
adjustment is not necessary. In examples No. 2 and No. 3, the
stratum-specific relative risks are similar, and both are either
higher or lower than 3. Confounding is present, and for each
example, adjustment, which will produce a weighted average
of the two stratum-specific relative risks, is appropriate.
In examples No. 4 and No. 5, the two stratum-specific
relative risks are very different; the stratification factor ap-
pears to modify the effect of the treatment on the outcome,
and the stratum-specific relative risks should not be com-
bined. The alternatives are either to present the stratum-
specific relative risks separately or to restrict the analysis to
subjects who are free of the potential confounding factor.
Confounding by indication simply cannot occur among sub-
jects who do not have the potential confounding factor, and
when the indication can be measured accurately, restriction
of the analysis to subjects without the indication excludes the
possibility of confounding by that indication.
A special form of restriction used to control for con-
founding by indication is the direct comparison of treatments
that have the same indications. For instance, beta-blockers
and calcium channel blockers are commonly used to treat
both hypertension and angina, and in this instance, users of
beta-blockers can serve äs the reference group for users of
calcium channel blockers. Even with this approach, con-
founding can still occur if the two groups differ in the severity
of disease underlying the indication.
Illustration of the Analytic Approaches
The data used in this example come from a case-control
study of patients with treated hypertension.10 The setting was
Group Health Cooperative of Füget Sound (GHC). During
the study period, cases had a first fatal or nonfatal myocardial
infarction, and controls were a stratified random sample of
GHC enrollees without a myocardial infarction and matched
to the cases on age, sex, and calendar year. Data collection
included a review of medical records and telephone inter-
views with consenting subjects. The use of antihypertensive
medications was assessed by data retrieved from the prospec-
tively collected information in the computerized pharmacy
database at GHC. The calcium channel blockers in use at
GHC were short-acting agents. Odds ratios were used to
estimate relative risks (RR).
In this case-control study, traditional risk factors such äs
current smoking (RR = 2.1), a history of diabetes (RR =
2.6), and the presence of clinical cardiovascular disease,
mainly angina (RR = 2.1), were clearly associated with^fhe
risk of myocardial infarction. To be confounding factors in
the association with myocardial infarction, these conditions
must also be associated with the exposure, which was anti-
hypertensive drug treatment. Although there was little asso-
Table 1. Hypothetical Effects of Stratification by a Potential Confounding Factor for an Association with a Grude (Unstratified)





























Grude and stratum-specific RRs are equal
Grude RR overestimates stratum-specific RRs
Grude RR underestimates stratum-specific RRs
Stratification factor modifies exposure effect
Stratification factor modifies exposure effect
* The relative risks are shown for each stratum of 5 hypothetical examples when the overall unadjusted and unstratified relative risk is 3.0. The stratification factor serves
äs a confounder when the crude RR consistendy overestimates or underestimates the stratum-specific RRs (äs in examples 2 and 3). The stratification factor serves äs an effect
modifier when stratum-specific RRs are clearly different (äs in examples 4 and 5).
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ciation between smoking and any of the drug treatments (see
Table 2 in ref. 10), diabetes and cardiovascular disease were
associated with several drug treatments.
With diuretics used äs the reference group, the use of
beta-blockers and calcium channel blockers, both indicated
for the treatment of angina, might be serving äs markers of
subjects with angina and convey a higher risk of myocardial
infarction. Table 2 summarizes the analysis stratified on the
presence or absence of previous clinical cardiovascular dis-
ease. Consider single drug users of beta-blockers. The unad-
justed relative risk was 1.26. In the stratified analysis, the
unadjusted relative risk was 1.83 among those with clinical
cardiovascular disease and 1.00 among those without clinical
cardiovascular disease. Several explanations are possible.
First, it is conceivable, but unlikely,19 that the use of beta-
blockers has an adverse effect on patients with existing clini-
cal cardiovascular disease. Second and more likely, this pat-
tern of relative risks is also what one would expect to see
when the use of a drug is serving äs a marker of a clinical
condition that itself carries an increased risk of the outcome.
This pattern of different risks across strata also appears
among users of calcium channel blockers, both those with
and those without diuretics. For this reason, restriction of the
analysis to subjects who were free of clinical cardiovascular
disease is appropriate when users of diuretics serve äs the
reference group. Adjustment for other potential confounding
factors, including diabetes, smoking, and pretreatment blood
pressures, had little effect on the relative risks observed
among subjects free of clinical cardiovascular disease (last set
of columns in Table 2).
The analysis presented in Table 3 is restricted to subjects
who used beta-blockers or calcium channel blockers, two
drugs that have the same indications. Here, the users of
beta-blockers serve äs the reference group. The unadjusted
relative risk for users of calcium channel blockers was 1.78.
Among subjects with and without cardiovascular disease, the
relative risks were 1.69 and 1.52, respectively. These
stratum-specific relative risks, both lower than 1.78, were
similar, so restriction was not necessary, and adjustment was
appropriate. The weighted average of the stratum-specific
relative risks was 1.59. The difference between 1.78 and 1.59
represents the confounding caused by the modest association
between the use of calcium channel blockers and the presence
of clinical cardiovascular disease. Moreover, there was little
additional confounding from other factors. After adjustment
for the other confounding factors, the relative risk was 1.57
(95% CI, 1.21-2.04). Thus, adjustment for cardiovascular
disease was adequate to control for confounding by indica-
tion in this example.
It is also possible for the dose of a drug to serve äs a
confounding factor. For example, subjects on higher doses of
calcium channel blockers might have more severe high blood
pressure. In analyses presented in the original paper,10 users
of low-dose beta-blockers served äs the reference group, and
increasing doses of calcium channel blockers were indeed
associated with higher risks of myocardial infarction (trend
P = .003). In contrast, increasing doses of beta-blockers were
also associated with lower risks of myocardial infarction
(trend P = .035). These dose-response findings, which went
in opposite directions, made confounding by dose äs a proxy
for the severity of high blood pressure largely an implausible
explanation.
Residual Confounding and Sensitivity Analyses
In particular studies, uncontrolled confounding may oc-
cur for several reasons. Some risk factors for an outcome may
not have been identified. Among the known risk factors for
an outcome, some may not have been measured for a variety
of reasons, including cost and difficulty. Even after adjust-
ment for known risk factors that are assessed in particular
studies, residual uncontrolled confounding may occur insofar
äs the confounding factors are measured with error.17'20'21
The possibility of residual uncontrolled confounding from
known or unknown factors is difficult to exclude, and, äs
such, it is one of the main criticisms of observational stud-
ies.14
Table 2. Association Between Myocardial Infarction and Antihypertensive Drug Therapies Stratified on the Presence or Absince of













































































































* Abbreviations: RR = relative risk, estimate from the odds ratio; RF = risk factor; CVD = cardiovascular disease; CI = confidence interval; Cntl = controls. The last
column of RRs was adjusted for age, gender, calendar year, smoking, diabetes, pre-treatment systohc biood pressure, duration of hypertension, physical activity and
education.
f P < 0.05.
*P<0.01.
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Table 3. Association Between Myocardial Infarction and Antihypertensive Drug Therapies Stratified on the Presence or Absence of







































* Abbreviations: RR = relative risk, estimate from the odds ratio; CVD = cardiovascular disease; Cntl = Controls; CI = confidence mterval; Ca-channel blockers :
calcium-channel blockers. Addmonal adjustment for nsk factors äs well äs CVD reduced the association from 1.59 down to 1.57 (95% CI = 1.21-2.04).
tp<0.01.
While this possibility of residual confounding often looms
large, there are limits to what this "unknown" confounding can
explain. The degree of confounding depends in a predictable
way on the prevalence of the putative confounding factor, the
level of its association with the disease, and the level of its
association with the exposure. Using methods adapted from
Rosenbaum and Rubin,22'23 Table 4 summarizes the effects of an
unknown confounding factor with prevalences of 20 and 40%.
This unknown factor can represent a single unknown or unmea-
sured factor, or it can be thought of äs incorporating the uncon-
trolled residual confounding that might result from measure-
ment error in a known risk factor.
In the case-control study,10 the risk of myocardial infarc-
tion in users of calcium channel blockers, compared with
Table 4. Sensitivity Analysis of the Effect of an Unknown Confounding Factor on the Association Between the Risk of Myocardial
Infarction and the Use of Calcium Channel Blockers (RR = 1.57) for Two Hypothetical Prevalences*
Prevalence of unknown confounder = 40%
Relative odds of
















































































































































Prevalence of unknown confounder = 20%
Relative odds of
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- Smoking Associations for which adjuslmenl
would reduce ttie RR from 1 57 lo 1 30
10 30 50 70 90
Relative odds of myocardial infarction
Figure 1. Effect of adjustment for an unknown confounder on a
relative risk (RR) of 1.57. The short-dashed line represents the
association of the unknown confounder with various combina-
tions of the myocardial infarction and calcium channel blocker
use required to move an RR of 1.57 down to 1.00. The long-
dashed line represents the associations required to move the RR
of 1.57 down to 1.30, which would have remained statistically
significant at the .05 level. Levels of associations with myocardial
infarction and calcium channel blocker use (CCB) use (respec-
tively) for typical risk factors such äs a history of diabetes (2.5
and 1.8), current Smoking (2.2 and 1.04), and clinical cardiovas-
cular disease (2.3 and 2.0) are marked on the figure.
users of beta-blockers, was 1.57 after adjustment for con-
founding factors that were measured. Table 4 represents the
influence of adjustment for a hypothetical unknown con-
founding factor on this association (RR = 1.57) according to
the strength of its association with the risk of myocardial
infarction (columns) and according to the strength of its
association with the use of calcium channel blockers (rows).
For instance, adjustment for an unknown confounding factor
that doubled the relative odds of myocardial infarction and
doubled the relative odds of the use of calcium channel
blockers would decrease the relative risk from 1.57 to 1.40 if
its prevalence was 40% and to 1.43 if its prevalence was
20%. With a prevalence of 20%, the unknown confounding
factor would have to increase the relative odds of disease by a
factor of 5 and simultaneously increase the odds of exposure
by a factor of 4 in order for adjustment to remove completely
(RR = 1.00) the association between calcium channel block-
ers and myocardial infarction in the case-control study. In
this study, we believe that plausible confounding factors with
such high levels of associations are unlikely to be present. In
these data, for instance, major risk factors such äs Smoking,
diabetes, and clinical cardiovascular disease increased the
risk of myocardial infarction by a factor of only 2.1 to 2.6.
Notice that in the first row and the first column of each
part of Table 4, the relative risk remains constant at 1.57.
This invariance illustrates the point that to be a confounder,
the potential confounding factor has to be associated both
with the exposure and with the outcome. Factors that are
unassociated (RR = 1.00) with either the exposure or the
outcome cannot be confounding factors. For any prevalence,
the degree of the associations determines the level of con-
founding.
Figure l illustrates the effects of adjustment for an un-
known confounding factor with a prevalence of 20% on a
relative risk of 1.57. The short-dashed line is an isobar that
connects the combinations of associations with myocardial
infarction and use of calcium channel blockers required to
reduce the relative risk from 1.57 to 1.00. The long-dashed
line connects the combinations required to reduce the relative
risk from 1.57to 1.30. Given its Standard error, a relative risk
of 1.30 is the lowest that would be statistically significant at
P = .05. Thus, any unknown or unmeasured confounding
factor whose associations with the myocardial infarction and
calcium channel blocker use place it below and to the left of
the long-dashed line would have reduced the relative risk
from 1.57 to a value larger than 1.30. Similarly, any con-
founding factor whose associations place it above and to the
right of the short-dashed line would have reduced the relative
risk from 1.57 to a value less than 1.0. The levels of associa-
tions for typical risk factors, including diabetes, smoking,
and cardiovascular disease, are shown in Figure 1. In other
words, individual unknown or unmeasured confounding fac-
tors similar in prevalence and predictive power to these major
risk factors would have had little or no effect on the Interpre-
tation of the association between the use of calcium channel
blockers and the risk of myocardial infarction in this study.
Concluding Observations
Several commentators have suggested that the mere pos-
sibility of unmeasured or unknown confounding requires
relative risks of 3 — or even 7 — before the fmdings of
observational studies can be believed.14'24 These hypothetical
unknown confounding factors would need to have extraor-
dinarily large associations with the outcome and the expo-
sure to move a relative risk from 7 down to l. As illustrated in
Figure l, a confounding factor with a prevalence of 20%
would have to increase the relative odds of both outcome and
exposure by factors of 4 to 5 before the relative risk of 1.57
would be reduced to 1.00.
The findings of observational studies can, of course, be
affected by other biases. Selective misclassification, when
present for either the exposure or the outcome, represents a
serious threat to validity. Other problems in the design or
analysis can have important effects on the results. Selection
bias is an example. In another case-control study of calcium
channel blockers and myocardial infarction,25 the authors
applied entry criteria that were different for the cases and the
controls. Insofar äs this difference in entry criteria afffcted
their fmdings, selection bias remains an alternative explana-
tion for their findings.
Despite their potential problems, observational studies
have provided important scientific evidence about the risks
associated with a number of risk factors, including medica-
tions such äs beta-agonists,26 exogenous estrogens,27""30 and
nonsteroidal anti-inflammatory agents.31'32 Observational
epidemiologic studies are often the only Option for assessing
safety. Although concern about potential confounding is
both important and appropriate, approaches to detecting and
controlling confounding are available, and, indeed, there are
mathematical limits to what unmeasured or unknown con-
founding can explain. As Walker and Stampfer suggest,9
confounding represents "an alternative storyline." Given the
data and the analysis presented, readers need to assess seri-
ously the plausibility of the alternative storylines.33
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